Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains

doi:10.1016/S0304-3940(98)00867-2

Neuroscience Letters

Volume 258, Issue 2, 18 December 1998, Pages 113-116

https://doi.org/10.1016/S0304-3940(98)00867-2 Get rights and content

Abstract

The Gallyas-Braak silver impregnation method revealed neurons containing well-defined intraneuronal granules in both Alzheimer's disease and normal control brains. The granules were immunostained prominently with the Alz-50 antibody and, to a lesser degree, with the tau-2 antibody, but not with other anti-tau antibodies examined. The areas of distribution of granule-containing neurons detected by the Gallyas-Braak method appeared to overlap with the reported main sites of subcortical distribution of neurofibrillary tangles. They, however, were not observed in the cerebral cortex, including the hippocampal region. The Alz-50 immunoreactive granules showed ultrastructural features similar to those of lysosomes or lipofuscin. These findings suggest that denatured tau might be degraded in lysosomes.

Section snippets

Acknowledgements

This research was supported by a Research Grant for Dementia from the Public Health Bureau of the Tokyo Metropolitan Government. We are grateful for generous gifts of antibodies from Drs. P. Davies (Department of Pathology, Albert Einstein College of Medicine), H. Mori (Department of Neuroscience, Osaka City University School of Medicine) and Y. Ihara (Institute for Brain Research, University of Tokyo).

References (17)

R. Endoh et al.
Lack of carboxyl terminal sequence of tau in ghost tangles of Alzheimer's disease
Brain Res.
(1993)
K. Iqbal et al.
A silver impregnation method for labeling both Alzheimer paired helical filaments and their polypeptides separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Neurobiol. Aging
(1991)
P. Liberini et al.
Alz-50 immunoreactivity in the central nervous system of adult rat and primate
Neurosci. Lett.
(1993)
H. Mori et al.
Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau
Neurosci. Lett.
(1995)
P.T. Nelson et al.
Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscopic study
Brain Res.
(1993)
D.B. Rye et al.
The distribution of Alz-50 immunoreactivity in the normal human brain
Neuroscience
(1993)
E. Bednarski et al.
Cytosolic proteolysis of τ by cathepsin D in hippocampus following suppression of cathepsin B and L
J. Neurochem.
(1996)
W. Byne et al.
Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat
J. Comp. Neurol.
(1991)

There are more references available in the full text version of this article.

Cited by (37)

Caspase-cleaved Tau-D<sup>421</sup> is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer's disease neurons
2016, Neurobiology of Aging
Citation Excerpt :
Having previously shown that FKBP52 decrease is strongly correlated with pathologic Tau accumulation in AD (Giustiniani et al., 2012), we wondered if the presence of Tau could be detected in FKBP52-positive vesicles (lysosomes, LEs and/or AVs) of AD neurons. At first, we used the conformation dependent Tau-2 antibody, which labels both typical NFTs and granular structures (Ikeda et al., 1998; Watanabe et al., 1992). A colocalization of Tau-2 with FKBP52 was found in vesicular structures (Fig. 5A, fluorescence profile [Z = 0.3 μm]).
Pathologic modifications of the Tau protein leading to neurofibrillary tangle (NFT) formation are a common feature of a wide range of neurodegenerative diseases known as tauopathies, which include Alzheimer's disease (AD). We previously showed that the immunophilin FKBP52 physically and functionally interacts with Tau, and we recently reported that FKBP52 levels are abnormally low in AD patients' brains. To decipher the mechanism of FKBP52 decrease in AD brains, we performed multiple labeling immunohistofluorescence and lysosomal purification using postmortem brain samples of healthy controls (n = 8) and AD (n = 20) patients. Confocal analysis revealed that FKBP52 localizes to the endolysosomal system. We also report FKBP52 colocalization with the truncated Tau-D⁴²¹ in the autophagy-endolysosomal system in some AD neurons and that the decrease of FKBP52 correlates with NFT formation. Additional experiments of autophagy inhibition in Tau-inducible SH-SY5Y cells allowed demonstrating FKBP52 release in the extracellular milieu. Our findings point out the possibility that FKBP52 could be abnormally released from NFTs negative neurons in AD brains in correlation with the early pathologic Tau-D⁴²¹ neuronal accumulation.
Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance
2014, Neuropharmacology
Citation Excerpt :
Autophagy is a highly conserved catabolic process, which is responsible for the clearance of aggregate-prone proteins and damaged cytoplasmic organelles within eukaryotic cells (Klionsky and Emr, 2000). As an intracellular aggregate-prone protein, hyperphosphorylated tau was observed to be cleared by autophagy in brain of normal individuals as well as patients with neurodegenerative tauopathies, suggesting that autophagy represented a clearance mechanism for abnormal tau protein and thus maintained intracellular homeostasis in brain (Ikeda et al., 1998; Schaeffer and Goedert, 2012; Wang et al., 2010). However, several lines of evidence indicated that the activity of autophagy was reduced in brain of patients and animal models with neurodegenerative tauopathies.
In a variety of neurodegenerative tauopathies including Alzheimer's disease, frontotemporal dementia and some types of Parkinson's disease, tau protein is abnormally hyperphosphorylated by several kinases and eventually aggregates to form neurofibrillary tangles, a neurotoxic pathological characteristic that closely correlates with cognitive impairments. Hence, targeting hyperphosphorylated tau protein has now been considered as a valid therapeutic approach for these neurodegenerative tauopathies. As a newly developed analog of rapamycin, temsirolimus was approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of renal cell carcinoma. Recent findings suggested that temsirolimus also provided beneficial effects in animal models of Huntington's disease and spinocerebellar ataxia type 3, two neurodegenerative diseases caused by accumulation of aberrant proteins within brain. To date, the therapeutic potentials of temsirolimus in neurodegenerative tauopathies have not been determined. Herein, we demonstrated for the first time that temsirolimus treatment effectively enhanced autophagic clearance of hyperphosphorylated tau in okadaic acid-incubated SH-SY5Y cells and in brain of P301S transgenic mice. Meanwhile, we showed that inactivation of glycogen synthase kinase-3β, the most important tau kinase, might contribute to the temsirolimus-induced reduction of tau hyperphosphorylation in these two tauopathy models. More importantly, temsirolimus administration rescued spatial learning and memory impairments in P301S transgenic mice. These findings highlight temsirolimus administration as a potential therapeutic strategy for neurodegenerative tauopathies.
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles
2012, FEBS Letters
Citation Excerpt :
As already mentioned, MVs could be originated from endocytic compartments. In addition, tau has been reported to be associated with membranous organelles like lysosomes [3,28,29]. Initially, by immunocytochemical analyses, we showed a partial colocalization of tau with LAMP1, a marker for late endosomes and lysosomes (Fig. 3A).
Chronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice
2009, Brain Research
Citation Excerpt :
Chronic cerebral hypoperfusion may affect each of these processes of Aβ metabolism, and the exact mechanisms should be indicated in the future study. Finally, it remains to be addressed in the future whether chronic cerebral hypoperfusion induces the abnormal phosphorylation of tau protein (Ikeda et al., 1998) and consequently accelerates synaptic dysfunction and cognitive deficits, since the Aβ load does not necessarily predict the magnitude of cognitive impairment (Giannakopoulos et al., 2003). We used human APP-Tg mice overexpressing the familial AD-linked mutation carrying a mutant form of the human APP bearing the both Swedish (K670N/M671L) and the Indiana (V717F) mutations (APPSwInd) (Mucke et al., 2000), which has been imported from the Jackson Laboratory (USA).
Chronic cerebral ischemia may accelerate clinicopathological changes in Alzheimer's disease. We have examined whether chronic cerebral hypoperfusion accelerates amyloid β deposition in amyloid protein precursor transgenic (APP-Tg) mouse. At 5, 8, and 11 months of age, C57Bl/6J male mice overexpressing a mutant form of the human APP bearing the both Swedish (K670N/M671L) and the Indiana (V717F) mutations (APPSwInd) and their litterrmates were subjected to either sham operation or bilateral carotid artery stenosis (BCAS) using microcoils with an internal diameter of 0.18 mm (short-period group). One month after the sham operation or BCAS, these animals were examined by immunohistochemistry for glial fibrillary acidic protein, amyloid β_1–40 (Aβ_1–40), amyloid β_1–42 (Aβ_1–42), as well as Western blotting and filter assay for Aβ. Another batch of the littermates of APPSwInd mice were subjected to either sham operation or BCAS at 3 months and were examined in the same manner after survival for 9 months (long-period group). In the BCAS-treated group, the white matter was rarefied and astroglia was proliferated. Amyloid β_1–40 immunoreactivity was found in a few axons in the white matter after BCAS, whereas Aβ_1–42 was accumulated in the scattered cortical neurons and the axons at ages of 6 months and thereafter in the short- and long-period groups. In the neuropil, both Aβ_1–40 and Aβ_1–42 were deposited in the sham-operated and BCAS-treated mice at ages of 9 and 12 months. There were no differences between the short-period group at ages of 12 months and the long-period group. Filter assay showed an increase of Aβ fibrils in the extracellular enriched fraction. Taken together, chronic cerebral hypoperfusion increased Aβ fibrils and induced Aβ deposition in the intracellular compartment and, therefore, may accelerate the pathological changes of Alzheimer's disease.
Pin1 protein associates with neuronal lipofuscin: Potential consequences in age-related neurodegeneration
2006, Experimental Neurology
Pin1 protein is a peptidyl-prolyl cis-trans isomerase that modulates the activity of a range of proteins involved in cell function. We and others have demonstrated neuronal Pin1 deficits in Alzheimer's disease (AD) and have shown similar deficits in frontotemporal dementia and in aging. Pin1 may, in fact, be a susceptibility factor; others have shown that Pin1 depletion causes apoptosis in HeLa cells. Further, patterns of AD pathology correlate with regions of lower Pin1 expression in normal human brain; Pin1 knockout mice suffer neurodegeneration; and Pin1 can ameliorate p-tau pathology by isomerizing p-tau, facilitating its trans-specific dephosphorylation and restoring its ability to bind to and restabilize microtubules and thence cytoskeletal integrity. Here, we report a novel localization of high levels of Pin1 with lipofuscin in aging neurons. This association could progressively drain available Pin1 and be deleterious to neuronal function during aging. We also show that Pin1 associates with lipofuscin when lipofuscin accumulations become marked and correlate with susceptibility to neurodegenerative disease. Our data are consistent with the possibility that neuronal Pin1 deficits may be a contributory factor in neurodegeneration associated with aging.
Low molecular weight species of tau in Alzheimer's disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing
2006, Neuroscience Letters
Gel electrophoresis and Western blotting of sarkosyl-insoluble fractions enriched in hyper-phosphorylated tau in Alzheimer disease (AD) have been used to analyze the pattern of phospho-tau by using different antibodies directed to the amino-terminal, core and carboxyl terminus of tau, and by using samples with increased artificial post-mortem delay in order to gain understanding on the characteristics of the band pattern and its vulnerability to post-mortem degradation. In addition to the typical profile of three major bands of 68, 64 and 60 kDa, several bands of lower molecular weight have been distinguished in frontal cortex homogenates in four AD cases stage V of Braak and Braak in optimal samples with 2 h of post-mortem delay. Lower bands, ranging from 60 to 22 kDa, are best seen with antibodies directed to the core of tau protein and, particularly, to the carboxy-terminus, thus suggesting the presence of truncated or cleaved forms of tau containing the C-terminal region. This pattern is not the result of post-mortem degradation, as artificial post-mortem delay of the same sample does not reveal the appearance of new bands with time. On the contrary, tau degradation, manifested as a reduction in the number and intensity of the bands, may occur between 8 and 26 h post-mortem and is universal in samples with post-mortem delays of 50 h.

View all citing articles on Scopus

View full text

Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains

Abstract

Section snippets

Acknowledgements

Brain Res.

Neurobiol. Aging

Neurosci. Lett.

Neurosci. Lett.

Brain Res.

Neuroscience

Cytosolic proteolysis of τ by cathepsin D in hippocampus following suppression of cathepsin B and L

J. Neurochem.

Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat

J. Comp. Neurol.